Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway

Basic Research in Cardiology

Volumn 107, Issue 3, 2012, Pages

  Yao, Yongwei ^a,b,c   Xu, Xuemei ^c   Zhang, Guohui ^a,b   Zhang, Yingyu ^a,b,c   Qian, Wei ^a   Rui, Tao ^a,b,c  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b Zhenjiang Institute of Cardiovascular Diseases   (China)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Apoptosis; Doxorubicin induced myocardial injury; HMGB1; JNK; Peroxynitrite

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; PEROXYNITRITE; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; PEROXYNITROUS ACID; PROTEIN KINASE INHIBITOR; TLR4 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; MOUSE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; HEART DISEASE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TIME; UPREGULATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOXORUBICIN; HEART DISEASES; HMGB1 PROTEIN; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCYTES, CARDIAC; PEROXYNITROUS ACID; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TOLL-LIKE RECEPTOR 4; TRANSFECTION; UP-REGULATION;

EID: 84859643452     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-012-0267-3     Document Type: Article

References (32)

1. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, Bea F, Hardt SE, Humpert PM, Bianchi ME, Mairbaurl H, Nawroth PP, Remppis A, Katus HA, Bierhaus A (2008) High-mobility group box-1 in ischemia- reperfusion injury of the heart. Circulation 117:3216-3226. doi: 10.1161/CIRCULATIONAHA.108.769331
2. Baker CS, Dutka DP, Pagano D, Rimoldi O, Pitt M, Hall RJ, Polak JM, Bonser RS, Camici PG (2002) Immunocytochemical evidence for inducible nitric oxide synthase and cyclooxygenase- 2 expression with nitrotyrosine formation in human hibernating myocardium. Basic Res Cardiol 97:409-415. doi:10.1007/s003950 200050
3. Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81:1-5. doi:10.1189/jlb. 0306164 (Pubitemid 46028489)
4. Bolton C, Scott GS, Smith T, Flower RJ (2008) The acute and chronic phases of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) are ameliorated by the peroxynitrite decomposition catalyst, 5,10,15,20-tetrakis(4-sulfonatophenyl) porphyrinato iron (III) chloride, (FeTPPS). Eur J Pharmacol 601:88-93. doi:10.1016/j.ejphar/2008.10.029
5. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103:239-252. doi:10.1016/s0092-8674(00)00116-1
6. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere- Querini P (2005) HMGB1: guiding immunity from within. Trends Immunol 26:381-387. doi:10.1016/j.it.2005.04.009 (Pubitemid 40835844)
7. Ewer MS, Ewer SM (2010) Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 7:564-575. doi:10.1038/nrcardio. 2010.121
8. Gardella S,Andrei C, FerreraD, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3:995-1001. doi:10.1093/embo-reports/kvf198 (Pubitemid 35256475)
9. Jiao XY, Gao E, Yuan Y, Wang Y, Lau WB, Koch W, Ma XL, Tao L (2009) INO-4885 [5,10,15,20-tetra[N-(benzyl-40-carboxylate)- 2-pyridinium]-21H,23H- porphine iron(III) chloride], a peroxynitrite decomposition catalyst, protects the heart against reperfusion injury in mice. J Pharmacol Exp Ther 328:777-784. doi:10.1124/jpet.108.144352
10. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S (2002) Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234-235:119-124. doi: 10.1023/A:1015976430790 (Pubitemid 34777848)
11. Li Y, Arita Y, Koo HC, Davis JM, Kazzaz JA (2003) Inhibitionof c-Jun N-terminal kinase pathway improves cell viability in response to oxidant injury. Am J Respir Cell Mol Biol 29:779-783. doi:10.1165/rcmb.2003-0087RC (Pubitemid 38045946)
12. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331-342. doi:10.1038/nri1594 (Pubitemid 40516158)
13. Loukili N, Rosenblatt-Velin N, Li J, Clerc S, Pacher P, Feihl F, Waeber B, Liaudet L (2011) Peroxynitrite induces HMGB1 release by cardiac cells in vitro and HMGB1 upregulation in the infarcted myocardium in vivo. Cardiovasc Res 89:586-594. doi: 10.1093/cvr/cvq373
14. Michel MC, Li Y, Heusch G (2001) Mitogen-activated protein kinases in the heart. Naunyn Schmiedebergs Arch Pharmacol 363:245-266. doi:10.1007/ s002100000363 (Pubitemid 32186523)
15. Mihm MJ, Coyle CM, Schanbacher BL, Weinstein DM, Bauer JA (2001) Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res 49:798-807. doi:10.1016/S0008- 6363(00)00307-2 (Pubitemid 32178383)
16. Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, Liaudet L, Szabo C, Pacher P (2009) Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 296:H1466-H1483. doi:10.1152/ajpheart.00795.2008
17. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L,Deb A, Szabo E, Ungvari Z, Wolin MS, Groves JT, Szabo C (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107:896-904. doi:10.1161/01.CIR. 0000048192.52098.DD (Pubitemid 36241050)
18. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279:7370-7377. doi:10.1074/jbc.M306793200 (Pubitemid 38294612)
19. Rui T, Cepinskas G, Feng Q, Kvietys PR (2003) Delayed preconditioningin cardiac myocytes with respect to development of a proinflammatory phenotype: role of SOD and NOS. Cardiovasc Res 59:901-911. doi:10.1016/S0008-6363(03)00502- 9 (Pubitemid 38366246)
20. Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191-195. doi:10.1038/nature00858 (Pubitemid 34773774)
21. Shen HM, Liu ZG (2006) JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 40:928-939. doi:10.1016/j.freeradbiomed.2005.10.056 (Pubitemid 43376002)
22. Singal PK, Siveski-Iliskovic N, Kaul N, Sahai M (1992) Significance of adaptation mechanisms in adriamycin induced congestive heart failure. Basic Res Cardiol 87:512-518. doi: 10.1007/BF00788661 (Pubitemid 23007997)
23. Takemura G, Fujiwara H (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. ProgCardiovasc Dis 49:330-352. doi:10.1016/j.pcad.2006.10.002 (Pubitemid 46295436)
24. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, Yang H, Li J, Tracey KJ, Geller DA, Billiar TR (2005) Thenuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201:1135-1143. doi:10.1084/ jem.20042614 (Pubitemid 40524681)
25. van Beijnum JR, Buurman WA, Griffioen AW (2008) Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11:91-99. doi:10.1007/s10456-008-9093-5
26. Volz HC, Laohachewin D, Seidel C, Lasitschka F, Keilbach K,Wienbrandt AR, Andrassy J, Bierhaus A, Kaya Z, Katus HA, Andrassy M (2012) S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-kappaBsignaling. Basic Res Cardiol 107:1-16. doi:10.1007/s00395- 012-0250-z
27. Volz HC, Seidel C, Laohachewin D, Kaya Z, Muller OJ, PlegerST, Lasitschka F, Bianchi ME, Remppis A, Bierhaus A, Katus HA, Andrassy M (2010) HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res Cardiol 105:805-820. doi:10.1007/s00395-010-0114-3
28. Xiao J, Moon M, Yan L, Nian M, Zhang Y, Liu C, Lu J, Guan H,Chen M, Jiang D, Jiang H, Liu PP, Li H (2012) Cellular FLICEinhibitory protein protects against cardiac remodelling after myocardial infarction. Basic Res Cardiol 107:1-21. doi:10.1007/ s00395-011-0239-z
29. Xu H, Su Z, Wu J, Yang M, Penninger JM, Martin CM, Kvietys PR, Rui T (2010) The alarmin cytokine, high mobility group box 1, is produced by viable cardiomyocytes and mediates the lipopolysaccharide- induced myocardial dysfunction via a TLR4/ phosphatidylinositol 3-kinase gamma pathway. J Immunol 184:1492-1498. doi:10.4049/jimmunol.0902660
30. Xu H, Yao Y, Su Z, Yang Y, Kao R, Martin CM, Rui T (2011) Endogenous HMGB1 contributes to ischemia-reperfusioninduced myocardial apoptosis by potentiating the effect of TNF- α/JNK. Am J Physiol Heart Circ Physiol 300:H913-H921. doi:10.1152/ajpheart.00703.2010
31. Yang H, Hreggvidsdottir HS, Palmblad K, WangH, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-AbedY, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U, Tracey KJ (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. ProcNatl Acad SciUSA107:11942-11947. doi:10.1073/pnas.1003893107
32. 53-induced inhibition of themammalian target of rapamycin pathway. Circulation 119:99-106. doi: 10.1161/CIRCULATIONAHA.108.799700